Entera Bio (NASDAQ:ENTX) Issues Earnings Results

Entera Bio (NASDAQ:ENTX) announced its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02, Zacks reports.

Entera Bio Price Performance

Shares of NASDAQ ENTX traded down $0.05 during mid-day trading on Friday, hitting $1.75. The company’s stock had a trading volume of 55,218 shares, compared to its average volume of 120,233. The stock has a market cap of $62.62 million, a price-to-earnings ratio of -6.73 and a beta of 1.62. The company’s fifty day simple moving average is $2.15 and its 200-day simple moving average is $2.02. Entera Bio has a one year low of $1.41 and a one year high of $3.35.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Tuesday, March 18th.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.